Dr. Lallas on Challenges With Immunotherapy in Genitourinary Malignancies

Partner | Cancer Centers | <b>Sidney Kimmel Cancer Center at Jefferson</b>

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses challenges with immunotherapy in genitourinary (GU) malignancies.

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses challenges with immunotherapy in genitourinary (GU) malignancies.

Most checkpoint inhibitors in GU cancers are still relatively new, says Lallas. Physicians want to be sure that they are giving the patients what they believe to be the best treatment, but as of now there is not a lot of information regarding immunotherapy in these diseases.

Additionally, the cost of these agents is very high, says Lallas, but as more positive data and knowledge about immunotherapy comes out in this disease, the cost may become more reasonable.